Drug intelligence / Profile preview

CAdTrio + pembrolizumab

Development stage: Unknown
Lead developer: Merck
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics
Administration: Intravenous, Intratumoral

Overview

CAdTrio + pembrolizumab is a combination therapy under investigation for cancer treatment. Pembrolizumab (Keytruda) is an immune checkpoint inhibitor that targets the PD-1 receptor, enhancing the immune system's ability to attack cancer cells[7][8]. CAdTrio refers to a group of three oncolytic adenoviruses, but specific details about its composition or mechanism are not widely published in major sources. The combination aims to leverage both direct tumor cell killing by oncolytic viruses and immune activation via checkpoint inhibition.

Other names: CAdTrio and pembrolizumabpembrolizumab plus CAdTrio

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on CAdTrio + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAdTrio + pembrolizumab.

Explore the full profile